Synonyms: MD 26479
Therapy Type: Small Molecule (timeline)
Target Type: Other Neurotransmitters (timeline)
Condition(s): Alzheimer's Disease
U.S. FDA Status: Alzheimer's Disease (Discontinued)
Company: Aventis Pharmaceuticals, Inc. (was Hoechst)
Suritozole is an inverse agonist at the GABA(A) receptor (Miller et al., 1992). GABA(A) receptor activity affects cholinergic function in the hippocampus and cerebral cortex (Richter et al., 1982; Wenk, 1984). This drug was found to improve memory performance in rats with scopolamine-induced memory acquisition deficits (Moran et al., 1992).
- Miller JA, Dudley MW, Kehne JH, Sorensen SM, Kane JM. MDL 26,479: a potential cognition enhancer with benzodiazepine inverse agonist-like properties. Br J Pharmacol. 1992 Sep;107(1):78-86. PubMed.
- Richter JA, Gormley JM. Inhibition of high affinity choline uptake in the hippocampus: studies on the site of pentobarbital action. J Pharmacol Exp Ther. 1982 Sep;222(3):778-85. PubMed.
- Wenk GL. Pharmacological manipulations of the substantia innominata-cortical cholinergic pathway. Neurosci Lett. 1984 Sep 28;51(1):99-103. PubMed.
- Moran PM, Kane JM, Moser PC. Enhancement of working memory performance in the rat by MDL 26,479, a novel compound with activity at the GABAA receptor complex. Brain Res. 1992 Jan 8;569(1):156-8. PubMed.
No Available Further Reading